Scarica l'app Stockscreener
0.3701
3.64%
-0.0149
Precedente Chiudi:
$0.385
Aprire:
$0.3834
Volume 24 ore:
701.60K
Relative Volume:
0.23
Capitalizzazione di mercato:
$46.32M
Reddito:
$36.86M
Utile/perdita netta:
$-171.67M
Rapporto P/E:
-0.2467
EPS:
-1.5
Flusso di cassa netto:
$-171.05M
1 W Prestazione:
+3.57%
1M Prestazione:
+4.60%
6M Prestazione:
-83.29%
1 anno Prestazione:
-86.61%
Intervallo 1D:
$0.3573
$0.3845
Intervallo di 1 settimana:
$0.303
$0.424
Portata 52W:
$0.2589
$2.83
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Nome
Mersana Therapeutics Inc
Settore
Industria
Telefono
617-498-0020
Indirizzo
840 MEMORIAL DRIVE, CAMBRIDGE
Confronta MRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.3717 | 44.94M | 36.86M | -171.67M | -171.05M | -1.50 |
|
ONC
Beigene Ltd Adr
|
236.78 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.52 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.73 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.32 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | William Blair | Outperform |
| 2024-11-15 | Ripresa | Citigroup | Buy |
| 2024-03-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-07-27 | Downgrade | Citigroup | Buy → Neutral |
| 2023-07-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Downgrade | Truist | Buy → Hold |
| 2023-07-27 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-06-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Iniziato | Guggenheim | Buy |
| 2023-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Iniziato | Citigroup | Buy |
| 2022-11-21 | Iniziato | Truist | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-04-29 | Iniziato | BTIG Research | Buy |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie
Mersana Therapeutics to Present at Upcoming Investor Conferences | MRSN Stock News - GuruFocus
Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus
Mersana Therapeutics (MRSN) Target Price Increased by Truist | MRSN Stock News - GuruFocus
Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com
Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria
Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com
Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan
Mersana Therapeutics (MRSN) Reports Lower Q1 Revenue and Shares - GuruFocus
Mersana Therapeutics Provides Business Update and Announces Firs - GuruFocus
Mersana Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewswire
Clinical Trial Results: Mersana's New Cancer Drug Achieves 31% Response Rate in Hard-to-Treat Tumors - Stock Titan
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Barclays PLC Sells 311,805 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Wedbush Expects Stronger Earnings for Mersana Therapeutics - Defense World
Petri Dish: Cancer biotech cuts staff; Lantheus sells business unit - The Business Journals
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Wedbush Cuts Price Target on Mersana Therapeutics to $3 From $4, Maintains Outperform Rating - marketscreener.com
Mersana Therapeutics announces restructuring plans; shares fall - TradingView
Mersana Therapeutics Announces Restructuring and Reprioritization Plan - citybiz
Mersana Therapeutics (MRSN) Announces Major Restructuring Strate - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Repri - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer | MRSN Stock News - GuruFocus
Mersana Therapeutics announces strategic cutbacks amid economic pressures - Investing.com
Mersana Therapeutics Announces Strategic Restructuring to Extend Cash Runway and Focus on Emi-Le Development - Nasdaq
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer - GlobeNewswire
Mersana Slashes Workforce by 55%, Doubles Down on Promising Breast Cancer Drug Pipeline - Stock Titan
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Mersana Therapeutics Inc [MRSN] stock for 2,061 USD was sold by Mandelia Ashish - knoxdaily.com
Renaissance Technologies LLC Has $867,000 Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc (MRSN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Mersana Therapeutics (MRSN) Expected to Announce Earnings on Thursday - Defense World
Mersana Therapeutics Inc Azioni (MRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):